StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck cancidas (caspofungin, legacy) — International sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q4 2022
35
Period ended Dec 31, 2022
Change on a year earlier
-20.5%
44 in Q4 2021
History
25 quarters
Since Q4 2016
Sources
17
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — International sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 202235-20.5%Form 10-K (filed 2023-02-24) ↗
Q3 2022Sep 30, 202242-25.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202239-26.4%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202252-5.5%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202144-26.7%Form 10-K (filed 2023-02-24) ↗
Q3 2021Sep 30, 202156+14.3%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202153+17.8%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2021Mar 31, 202155+5.8%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2020Dec 31, 202060+7.1%Form 10-K (filed 2023-02-24) ↗
Q3 2020Sep 30, 202049-21.0%Form 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2020Jun 30, 202045-29.7%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202052-13.3%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 201956-16.4%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 201962-19.5%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201964-22.9%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201960-31.8%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗

Breakdown

What makes up cancidas (caspofungin, legacy) — international sales ($m)

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) — International sales ($M) ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_cancidas_intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.